# Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes

> **NCT00118963** · PHASE4 · COMPLETED · sponsor: **Steno Diabetes Center Copenhagen** · enrollment: 102 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Metformin
- **DRUG:** Insulin BIAsp30 (Novolog 70/30)
- **DRUG:** Repaglinide
- **DRUG:** Placebo-Metformin
- **DRUG:** Placebo-Repaglinide

## Key facts

- **NCT ID:** NCT00118963
- **Lead sponsor:** Steno Diabetes Center Copenhagen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2008-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00118963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00118963, "Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00118963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*